Nvidia’s Q3 FY27: The Reassurance Before the Storm
Nvidia faces allegations over China and Southeast Asia sales, financial reporting and governance ahead of Q3 FY27 results.
Nvidia faces allegations over China and Southeast Asia sales, financial reporting and governance ahead of Q3 FY27 results.
@evfcfaddict @alluvialcapital $BWEL will work eventually
Tom likes the stock. $MKL adding >10% buyback auth, now ~15% buyback auth outstanding.
Target Posts Strongest Sales Growth in Years as Focus on New Products, Value Pays Off $TGT
TJX Raises Full-Year Outlook, Expects Sales Trends to Accelerate Through Holiday Season $TJX
Cal-Maine Foods to Cull 1.76 Million Birds After Florida Facility Tests Positive for Bird Flu $CALM
Nvidia faced China workaround enforcement concerns as technology fell 6%; energy rose 4.5%, while the company raised eFY28 revenue growth…
MiniMed's 15.8% Q1 organic growth and 20% U.S. pump-volume increase support a product-cycle recovery as split-off selling fades.
Nvidia reported $115.8 billion in Q3 revenue, up 103%, and guided $130 billion, while Jensen Huang’s resignation left Colette Kress as…
Pfizer’s Q3 revenue reached $16.58 billion, launched and acquired products grew 32%, and FY26 guidance rose to $62 billion to $64 billion.
NVIDIA’s fiscal third-quarter 2027 results are its first earnings report since Jensen Huang’s resignation as CEO.
UFP Industries trades near its 2022 price despite EPS falling 62%; a $95–$105 valuation assumes $6.30 normal-year EPS, with freight and…
Nvidia reported $115.8 billion in Q3 revenue, up 103%, and raised its fiscal 2028 growth outlook to 75% as interim CEO Colette Kress…
Century Aluminum (CENX) could benefit from U.S. tariffs, Midwest aluminum premiums and constrained global supply, with the stock trading…
Figma grew Q3 revenue 43% to $391.4 million, raised FY2026 guidance to nearly $1.5 billion and guided Q4 above consensus despite the stock…
Nvidia raised its fiscal 2028 growth outlook, but shares reversed as investors focused on uncertainty beyond January 2028.
ANAB · long AnaptysBio is pitched for a 50% to 80% return over four to six weeks after its April 2026 taxable spin-off of R&D-heavy operations.
Veeva plans Falcon agents for pharmacovigilance, clinical-trial documents and regulatory writing, targeting multibillion-dollar…
REIT holdings outperformed in H1 2026, with Veris Residential sold in a $19-per-share take-private and FrontView REIT trimmed after a 78%…
IREN awarded each co-CEO roughly 9 million RSUs, about 2.5% of shares and $400 million, in exchange for no further equity grants until…
Rocket Lab and Firefly won access to US space contracts as AI-driven HBM demand tightens memory-chip supply through 2027.
Ukraine’s Black Sea attacks on CPC infrastructure threaten Kazakhstan’s 1.4 million bpd oil export route through Russia, putting Chevron’s…
Intel's silicon photonics CPO work shows precise 16-wavelength lasers but suffers SOA four-wave-mixing noise and weaker link performance…
Nubank's 140 million customers, 20% efficiency ratio and 30% ROE frame whether its high-teens P/E reflects a scalable fintech or a maturing…
NewLake Capital Partners’ potential NYSE or Nasdaq uplisting contrasts with falling revenue, three vacant properties and an 88% AFFO payout…
DoorDash’s integrated autonomous-delivery strategy contrasts with Uber’s 2026 divestment of Serve Robotics, its former delivery-robot…
Every publication on this site, hand-picked.
Every account on this site, hand-picked.
Ordered by how often our editor reaches for them.